-
公开(公告)号：US20240158785A1
公开(公告)日：2024-05-16
申请号：US18411929
申请日：2024-01-12
发明人： Tomoyuki Igawa , Shigero Tamba , Shun Shimizu , Kanako Tatsumi , Shojiro Kadono , Hiroki Kawauchi , Kazuhiro Ohara , Masayuki Matsushita , Takashi Emura , Masaki Kamimura
IPC分类号： C12N15/10 , C07K16/00 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/42 , C07K16/44 , C40B50/06
CPC分类号： C12N15/1093 , C07K16/00 , C07K16/005 , C07K16/248 , C07K16/2809 , C07K16/2863 , C07K16/2866 , C07K16/30 , C07K16/4283 , C07K16/44 , C40B50/06 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/92
摘要： An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries. Various diseases originating from target tissues can be treated in a target tissue-specific manner by using the antigen-binding molecules of the present invention.
-
公开(公告)号：US11739149B2
公开(公告)日：2023-08-29
申请号：US16704464
申请日：2019-12-05
发明人： Tomoyuki Igawa , Shojiro Kadono , Naoka Hironiwa , Mika Sakurai
CPC分类号： C07K16/2809 , C07K16/2848 , C07K16/2863 , C07K16/2866 , C07K16/2875 , C07K16/2896 , C07K16/30 , C07K16/4283 , C07K2317/24 , C07K2317/31 , C07K2317/526 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2319/00 , C07K2319/70
摘要： The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.
-
公开(公告)号：US11673947B2
公开(公告)日：2023-06-13
申请号：US16539765
申请日：2019-08-13
发明人： Tomoyuki Igawa , Shigero Tamba , Kanako Tatsumi , Shun Shimizu , Shojiro Kadono
IPC分类号： C07K16/00 , C07K16/24 , C07K16/18 , C07K16/28 , C07K16/30 , C07K16/44 , G01N33/68 , A61K39/00
CPC分类号： C07K16/248 , C07K16/00 , C07K16/005 , C07K16/18 , C07K16/2866 , C07K16/30 , C07K16/44 , G01N33/6845 , G01N33/6869 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/732 , C07K2317/92 , G01N2333/5412 , G01N2500/00 , G01N2500/20
摘要： The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.
-
公开(公告)号：US10961530B2
公开(公告)日：2021-03-30
申请号：US15100934
申请日：2014-12-04
发明人： Tomoyuki Igawa , Shigero Tamba , Shun Shimizu , Kanako Tatsumi , Shojiro Kadono , Hiroki Kawauchi , Kazuhiro Ohara , Masayuki Matsushita , Takashi Emura , Masaki Kamimura
IPC分类号： C40B50/06 , C12N15/10 , C07K16/28 , C07K16/24 , C07K16/00 , C07K16/42 , C07K16/44 , C07K16/30
摘要： An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries. Various diseases originating from target tissues can be treated in a target tissue-specific manner by using the antigen-binding molecules of the present invention.
-
公开(公告)号：US20150299296A1
公开(公告)日：2015-10-22
申请号：US14423269
申请日：2013-08-23
发明人： Hitoshi Katada , Shojiro Kadono , Futa Mimoto , Tomoyuki Igawa
CPC分类号： C07K16/00 , A61K9/0019 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/303 , C07K2317/52 , C07K2317/524 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/92 , C07K2317/94 , C07K2319/30 , Y02A50/412
摘要： An objective of the present invention is to provide an Fc region variant with enhanced FcγRIIb-binding activity, and/or enhanced binding selectivity to FcγRIIb compared to FcγRIIa (type R), as compared to those of a polypeptide containing an Fc region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing FcγRIIb-binding activity and also enhancing binding selectivity to FcγRIIb compared to FcγRIIa (type R).It was found that a polypeptide containing an antibody Fc region variant that contains an amino acid sequence in which an amino-acid alteration at position 238 (EU numbering) is combined with other specific amino-acid alterations enhances FcγRIIb-binding activity, and/or enhances binding selectivity to FcγRIIb compared to FcγRIIa (type R).
摘要翻译： 本发明的目的是提供与FcγRIIa（R型）相比具有增强的FcγRIIb结合活性和/或增强的对FcγRIIb的结合选择性的Fc区变体，与含有Fc区的Fc区相比， 没有引入氨基酸改变; 包括Fc区变体的多肽; 含有该多肽的药物组合物; 预防包括该药物组合物在内的免疫性炎性疾病的治疗或预防剂; 其制造方法; 以及与FcγRIIa（R型）相比增强FcγRIIb结合活性和增强与FcγRIIb的结合选择性的方法。 已经发现含有含有氨基酸序列的抗体Fc区变体的多肽，其中第238位的氨基酸改变（EU编号）与其他特异性氨基酸改变相结合增强FcγRIIb结合活性，和/或 与FcγRIIa（R型）相比，增强与FcγRIIb的结合选择性。
-
公开(公告)号：US11154615B2
公开(公告)日：2021-10-26
申请号：US15525603
申请日：2015-11-11
发明人： Tomoyuki Igawa , Shojiro Kadono , Naoka Hironiwa , Mika Sakurai
摘要： The present inventors have successfully prepared a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, the antigen-binding molecules each comprising an antibody variable region that has binding activity against a first antigen and a second antigen different from the first antigen, but does not bind to the first antigen and the second antigen at the same time. Use of the library of the present invention allows the obtainment of a variable region having enhanced ability to bind to the first antigen and the production of a bispecific antibody against the first antigen and a cancer antigen. Moreover, the present inventors have also successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against three different antigens, but does not bind to these antigens at the same time.
-
公开(公告)号：US10919953B2
公开(公告)日：2021-02-16
申请号：US14423269
申请日：2013-08-23
发明人： Hitoshi Katada , Shojiro Kadono , Futa Mimoto , Tomoyuki Igawa
IPC分类号： C07K16/00 , C12P21/08 , A61K39/395 , C07K16/30 , C07K16/28 , C07K1/00 , A61K9/00 , A61K39/00
摘要： An objective of the present invention is to provide an Fc region variant with enhanced FcγRIIb-binding activity, and/or enhanced binding selectivity to FcγRIIb compared to FcγRIIa (type R), as compared to those of a polypeptide containing an Fe region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing FcγRIIb-binding activity and also enhancing binding selectivity to FcγRIIb compared to FcγRIIa (type R).
It was found that a polypeptide containing an antibody Fc region variant that contains an amino acid sequence in which an amino-acid alteration at position 238 (EU numbering) is combined with other specific amino-acid alterations enhances FcγRIIb-binding activity, and/or enhances binding selectivity to FcγRIIb compared to FcγRIIa (type R).-
公开(公告)号：US20180155451A1
公开(公告)日：2018-06-07
申请号：US15860163
申请日：2018-01-02
发明人： Futa Mimoto , Taichi Kuramochi , Tomoyuki Igawa , Meiri Kawazoe , Hitoshi Katada , Hirotake Shiraiwa , Shojiro Kadono
IPC分类号： C07K16/46 , C07K16/00 , C07K16/18 , C07K16/22 , C07K16/28 , C07K16/36 , C07K16/30 , G01N33/566 , C07K1/107
CPC分类号： C07K16/46 , C07K1/1075 , C07K16/00 , C07K16/18 , C07K16/22 , C07K16/2866 , C07K16/30 , C07K16/303 , C07K16/36 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/72 , C07K2317/732 , C07K2317/92 , C07K2317/94 , G01N33/566
摘要： The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved Fc region function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.
-
公开(公告)号：US20230257470A1
公开(公告)日：2023-08-17
申请号：US18298743
申请日：2023-04-11
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Kenta Haraya , Yuki Iwayanagi , Tatsuhiko Tachibana , Futa Mimoto , Taichi Kuramochi , Hitoshi Katada , Shojiro Kadono
CPC分类号： C07K16/2866 , C07K16/303 , C07K16/08 , C07K16/18 , C07K2317/524 , C07K2317/72
摘要： The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fcγ receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
-
公开(公告)号：US20220242934A1
公开(公告)日：2022-08-04
申请号：US17484003
申请日：2021-09-24
发明人： Tomoyuki Igawa , Naoka Hironiwa , Shojiro Kadono , Atsushi Matsuo , Taichi Kuramochi , Futa Mimoto
摘要： The present inventors have successfully prepared an antibody Fc region dimer that has binding activity against each of an antigen and FcγR, but does not bind to the antigen and the FcγR at the same time, and a polypeptide comprising the Fc region dimer. The present invention enables the preparation of a multispecific binding polypeptide capable of avoiding an adverse reaction that may be caused by its binding to an antigen and FcγR at the same time. Thus, the present invention provides a polypeptide suitable as a drug.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.032 秒)
